David Fittingoff, MD
Endocrinology, Diabetes & Metabolism · West Hills, CANPI 1902817901
Payments from drug & device makers
Across 1,821 payments — averaging $185.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$175K
- AbbVie$136K
- Novo Nordisk$4K
- Mannkind Corporation$3K
- Amgen$3K
- Dexcom, Inc.$3K
- plus $14K from 34 others
Across 15 payments — averaging $111.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 812 | $174,950 |
| AbbVie | 17 | $135,770 |
| Novo Nordisk | 250 | $4,314 |
| Mannkind Corporation | 106 | $3,241 |
| Amgen | 51 | $3,023 |
| Dexcom, Inc. | 81 | $2,533 |
| Abbott | 71 | $1,943 |
| AstraZeneca(2 entities) | 48 | $1,584 |
| Boehringer Ingelheim | 65 | $1,570 |
| Lilly USA, LLC | 56 | $1,265 |
| Xeris Pharmaceuticals, Inc. | 54 | $1,172 |
| Eli Lilly | 19 | $1,066 |
| Sanofi-aventis U.S. LLC | 38 | $830 |
| Corcept Therapeutics | 25 | $713 |
| Medtronic(2 entities) | 21 | $613 |
| Tandem Diabetes Care, Inc. | 9 | $431 |
| Novartis | 16 | $394 |
| Insulet Corporation | 7 | $354 |
| Radius Health, Inc. | 13 | $324 |
| Madrigal Pharmaceuticals | 9 | $258 |
| Ascendis Pharma Endocrinology Inc | 6 | $249 |
| Bayer | 5 | $208 |
| BETA Bionics, Inc. | 8 | $188 |
| GSK | 3 | $158 |
| Amarin Pharma, Inc. | 3 | $156 |
| Intuitive Surgical | 1 | $115 |
| Sequel Med Tech, LLC | 5 | $104 |
| Astellas Pharma US Inc | 2 | $64 |
| Lexicon Pharmaceuticals, Inc. | 2 | $59 |
| Alvogen Inc | 3 | $52 |
| Valeritas, Inc. | 1 | $47 |
| Merck | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $44 |
| Almatica Pharma LLC | 3 | $44 |
| Shire North American Group Inc | 1 | $24 |
| Boehringer Ingelheim International GmbH | 1 | $22 |
| Ascensia Diabetes Care US Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Pfizer | 1 | $13 |
How this compares
$337,994 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in West Hills
- Dan StrejaWest Hills$3M
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
- Shlomo MelmedLos Angeles$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.